Pasireotide has a 30- to 40-fold higher affinity for SSTR5 and lower affinity for SSTR2 compared with octreotide, which is why pasireotide has been attributed with potentially greater clinical efficacy in acromegaly than first-generation SSA (9, 11, 12). Here, SSTR2 is linked to acromegaly.